MiNK Therapeutics Stock Skyrockets 643% On Cancer Remission Case

(RTTNews) - MiNK Therapeutics, Inc. (INKT) shares surged 643.52 percent to $57.47 after the publication of a breakthrough case study in Nature's Oncogene highlighted a complete and lasting remission in a patient with advanced testicular cancer treated with the company's iNKT cell therapy, agenT-797.

Shares opened at $21.07 and soared as high as $58.50 on extreme volume of 25.9 million, compared to an average of just 7,585 on the Nasdaq. The stock now sits at the upper end of its 52-week range of $4.56 to $58.50.

The patient had previously failed multiple therapies, including chemotherapy and checkpoint inhibitors, but achieved full remission with a single infusion combined with nivolumab—remaining disease-free for over two years.